Association of CYP2C19*2 and *17 genetic variants with hypertension in Pakistani population

Sana Riaz1,2, Atika Mansoor1, Saima Siddiqi1, Muhammad Usman Tareen2, Sana Rubab2, Ayesha Bathool2, Anwarullah3, Aneesa Sultan2*

1Institute of Biomedical Genetic Engineering (IBGE), 24 Mauve Area, G-9/1, Islamabad, 2Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan

*For correspondence: Email: aneesa@qau.edu.pk; Tel: +92-51-90643223

Sent for review: 19 May 2019 Revised accepted: 13 March 2019

Abstract

Purpose: To investigate the association of *2 and *17 single nucleotide polymorphisms (SNPs) of CYP2C19 gene with hypertension in Pakistani population.

Methods: The study was conducted on 527 hypertensive patients and 530 unrelated healthy controls from selected regions of Pakistan. DNA was extracted from leukocytes and all patients and controls were genotyped for two SNPs (rs4244285 and rs12248560) of CYP2C19 gene by allele specific polymerase chain reaction (AS-PCR).

Results: Multi-allelic polymorphism in CYP2C19 identified four distinct phenotypes known as ultra-rapid metabolizer (UM), extensive metabolizer (EM), intermediate metabolizer (IM) and poor metabolizer (PM) in hypertensive patients and controls. For CYP2C19*2 polymorphisms, overall wild type and mutant allele frequency were 75 and 25 % in hypertensive patients, and 64.2 and 35.8 % in controls. For CYP2C19*17 polymorphisms, the overall wild type and mutant allele frequency were 66.6 and 33.4 % in hypertensive patients and 75.6 % and 24.4 % in controls. Significant difference in allele frequencies for CYP2C19*2 and *17 was demonstrated between hypertensive and non-hypertensive subjects.

Conclusion: To the best of our knowledge, this is the first report on CYP2C19 frequencies in hypertensive Pakistani patients. The finds should help clinicians to determine a suitable optimal dosage of some drugs in order to reduce side effects.

Keywords: CYP2C19, Genotyping, Single nucleotide polymorphism, Adverse drug reactions, Pakistani population

INTRODUCTION

Cytochrome P450 2C19 (CYP2C19), an important enzyme of the cytochrome P450 family, is involved in the metabolism of several drugs. Inter-individual variation in treatment response is due to genetic polymorphisms in CYP2C19 [1]. PM of CYP2C19*2 sustain omeprazole for a longer time period which helps in stronger inhibition of gastric acid secretion for longer interval [2]. Psychiatric patients having CYP2C19*17 allele show 42 % lower escitalopram serum levels showing high risk of treatment failure [3]. On the other hand,
CYP2C19*17 allele carriers have reduced risk of breast cancer occurrence [4].

US FDA has issued a “Black Box” to Clopidogrel in March 2009, recommending CYP2C19 genotyping before prescribing Clopidogrel and using guidelines available for Clopidogrel drug monitoring [5]. Another study reported that PM of CYP2C19 had higher levels of Giliazide suggesting CYP2C19 role in Giliazide clearance [6]. CYP2C19 PM genotype in cirrhotic patients having hepatitis C virus is associated with higher risk of developing hepatocellular carcinoma [7]. Previous studies revealed that CYP2C19 rs10509676 variant homozygote (AA genotype) was associated with HTN [8]. The present study was carried out to explore the association of *2 and *17 alleles of CYP2C19 and how it’s affecting recent treatment regimes.

EXPERIMENTAL

Subjects

The study group included 1057 subjects, consisting of 527 hypertensive patients and 530 controls from representative regions of Pakistan. The study was conducted in compliance with the Declaration of Helsinki [9] and was approved by the ethical Committee and Institutional Review Board (IRB) of Quaid-i-Azam University, Islamabad (#IRB-QAU-97). A written informed consent was obtained from all subjects before participation in the study.

Genotyping

Blood samples (5 ml in tubes containing EDTA) were drawn from the subjects and kept at 4 °C until DNA extraction from peripheral blood leukocytes by phenol chloroform method. CYP2C19 alleles CYP2C19*2 (c.G681A; rs4244285) and CYP2C19*17 (c.C806T; rs12248560) were genotyped by Allele-specific (AS-PCR) and the primer data is given in supplementary data (Table 2 and 3). In each 20 µL PCR reaction, 1X PCR buffer (2.5 µL) (Fermentas), 1.5 mM MgCl₂, 0.2 mM dNTPs, 0.5 µM each of forward and reverse primers, 0.2 units of Taq DNA polymerase (Fermentas) and 100 ng of DNA samples were used.

PCR amplification of CYP2C19*2 region was carried out by initial denaturation at 95 °C for 5 min, followed by 30 cycles of denaturation at 94 °C for 1 min, annealing at 62 °C for the amplification of “A” allele-specific DNA fragment and 60 °C for “G” allele-specific DNA fragment for 40 seconds, extension at 72 °C for 1 min followed by final extension at 72 °C for 5 min. The thermal profile for the amplification of CYP2C19*17 was similar to CYP2C19*2 amplification except annealing at 58 °C for both alleles. Once DNA amplification was done, the PCR products were run on 2 % agarose gel in order to confirm the genotype of patients. The phenotype was inferred theoretically from the genotype.

Statistical analysis

Association between the CYP2C19*2 and CYP2C19*17 variants and HTN was determined using SPSS version 20.0 [10]. The level of significance for all the results was set at p < 0.05. Chi-square test was used to test the significance of the Hardy-Weinberg equilibrium of the polymorphism of the two genes in the entire data of the patient and the control groups.

RESULTS

The distribution of CYP2C19 genotypes and allele frequencies for the *2 and *17 SNPs within the hypertensive patient and control groups are presented in Table 1. Distribution of genotypes for the *2 polymorphism in hypertensive patients was 60 % homozygous wild type (CYP2C19*1/*1), 10 % homozygous mutant (CYP2C19*2/*2), 30 % heterozygous (CYP2C19*1/*2); and in controls 40 % homozygous wild type (*1/*1), 20 % homozygous mutant (*2/*2) and 40 % heterozygous (*1/*2). For CYP2C19*2 polymorphisms, overall wild type and mutant allele frequency was 75 and 25 % in hypertensive patients and 64.2 and 35.8 % in controls.

Similarly distribution of genotypes for the *17 polymorphism was 40 % homozygous wild type (*1/*1), 10 % homozygous mutant (*17/*17) and 50 % heterozygous (*1/*17, *2/*17); and in controls 60 % homozygous wild type (*1/*1), 10 % homozygous mutant (*17/*17) and 30 % heterozygous (*1/*17, *2/*17). Whereas for CYP2C19*17 polymorphisms, the overall wild type and mutant allele frequency was 66.6 % and 33.4 % in hypertensive patients and 75.6 % and 24.4 % in controls. On analyzing the data it came out that, out of 527 cases registered, 48 % were males and 52 % were females. In our case frequency of primary and secondary hypertension were (70 % and 30 %) respectively. Our results shows that among cases, 97 % were married, 50 % had a positive family history of hypertension, 55 % were obese, 20 % were smokers, 60 % were non-working, 40 % are taking normal diet and 60 % undergoes normal sleep. Cases were stratified according to the
association of other complications into 5 subgroups including Gp I: hypertension with diabetes (30%); Gp II: hypertension with cardiac complication (10%); Gp III: hypertension with renal complications (10%); Gp IV: hypertension with other diseases (10%); Gp V: no disease (30%). According to medication details, 60% of the patients received monotherapy while 40% patients received combination therapy; 15% patients did not take any medication. Regarding drug classes, CYP2C19*2 is more prevalent in patients taking angiotensin converting enzyme (ACE) inhibitor (30.35%), followed by beta blocker (BB) (20.68%), Calcium channel blockers (CCB) (18.49%), angiotensin receptor blocker (ARB) (16.41%) and Diuretic (12.50%). Whereas, CYP2C19*17 shows highest frequency in ARB (30.14%) followed by CCB (28.47%), Diuretic (25%) BB (24.13%) and ACE inhibitor (2.75%). However, CYP2C19 (*2/*2) mutant allele was more frequent in cardiac patients (26%) followed by other diseases (20%), renal patients and patients who did not take any medication (19%) and diabetics (16%). Moreover CYP2C19 (*17/*17) allele showed high prevalence in Diabetics (22%) followed by Cardiac patients (21%), patients not taking any medication (20%), patients having other diseases (19%), patients on renal diseases (18%). Finally, the distribution of alleles and genotypes of CYP2C19*2 and *17 showed a significant difference between hypertensive patients and normal controls (p ≤ 0.05) which suggests that CYP2C19*2 and *17 are associated with hypertension in the Pakistani population studied.

**DISCUSSION**

CYP2C19*2 allele frequency in the present study population is (35.8%). This result was consistent with those reported by Asian populations (14-39%) [11], in India (40.2%) [12], Philippines (39%) [11], Chinese-Han (37%) [13], Lure (35%) [14], Hakka (31%) [15] and Japan (30%) [16].

**Table 1:** Genotype (%) among patients and controls

| Variable              | Patients (n=527) | Control (n=530) | OR     | P-value | CI       |
|-----------------------|-----------------|----------------|--------|---------|----------|
| **CYP2C19*2**         |                 |                |        |         |          |
| Homozygous Wildtype   | 307 (60%)       | 231 (40%)      | 0.55   | 0.433-0.706 |        |
| Heterozygous          | 174 (30%)       | 219 (40%)      | 1.42   | 1.111-1.835 |        |
| Homozygous Mutant     | 46 (10%)        | 80 (20%)       | 1.85   | <0.00001 | 1.265-2.731 |
| Alleles               |                 |                |        |         |          |
| Wildtype              | 788 (75%)       | 681 (64.2%)    | 0.60   | 0.502-0.731 |        |
| Mutant                | 266 (25%)       | 379 (35.8%)    | 1.64   | 0.000 | 1.367-1.988 |
| **CYP2C19*17**        |                 |                |        |         |          |
| Homozygous Wildtype   | 213 (40%)       | 332 (60%)      | 2.47   | 1.93-3.165 |        |
| Heterozygous          | 276 (50%)       | 137 (30%)      | 0.31   | 0.244-0.410 |        |
| Homozygous Mutant     | 38 (10%)        | 61 (10%)       | 1.67   | <0.00001 | 1.094-2.558 |
| Alleles               |                 |                |        |         |          |
| Wildtype              | 702 (66.6%)     | 801 (75.6%)    | 1.55   | 1.282-1.874 |        |
| Mutant                | 352 (33.4%)     | 259 (24.4%)    | 0.644  | 0.00005 | 0.533-0.779 |

**Table 2:** Primers for CYP2C19*2

| Primer     | Sequence (5’-3’) | Length | Melting temp (°C) | Size (bp) | Type of PCR product |
|------------|------------------|--------|------------------|-----------|---------------------|
| 2C19*2 F   | CAGAGCTTGGCAATATTGTATC | 22     | 57.1             | 291       | Control             |
| 2C19*2 R   | ATACGCAAGCAGTCACATAAC | 21     | 57.4             | 169       | A allele fragment   |
| 2C19*2 A   | GTATTTGGTTAGGTTCTCT | 20     | 52.3             | 202       | G allele fragment   |
| 2C19*2F    | CAGAGCTTGGCAATATTGTATC | 22     | 57.1             | 169       | A allele fragment   |
| 2C19*2G    | ACTATCGTTATATTCCCG | 21     | 55.6             | 202       | G allele fragment   |

**Table 3:** Primers for CYP2C19*17

| Primer     | Sequence (5’-3’) | Length | Melting temp (°C) | Size (bp) | Type of PCR Product |
|------------|------------------|--------|------------------|-----------|---------------------|
| 2C19*17F   | AAGAAGCGTTTTACTCTCAAG | 21     | 55.5             | 507       | Control             |
| 2C19*17R   | AAACACTTTACATTAAACC | 22     | 56.6             | 218       | T allele fragment   |
| 2C19*17T   | TGCTCTGTCTCTCAAGTA | 20     | 52.3             | 202       | C allele fragment   |
| 2C19*17R   | AAACACTTTACATTAAACC | 22     | 56.6             | 202       | C allele fragment   |
| 2C19*17F   | AAGAAGCGTTTTACTCTCAAG | 21     | 55.5             | 330       | C allele fragment   |
| 2C19*17C   | ATTATCCTTTACACAGAGATG | 22     | 54.7             | 330       | C allele fragment   |
Similarly CYP2C19*17 allele frequency in our Pakistani population is (24.4 %) and were close to other populations namely, Iran (21.7 %) [17], Saudi Arabia (25.7 %) [18], Turkey (24.4 %) [19] and Germany (25.5 %) [20].

HTN is a major public health issue affecting approximately 1 billion people worldwide [21]. Among hypertensive drugs, most commonly prescribed were CCB and BB [22]. Previous studies show that in case of severe kidney patients, ACE inhibitor or ARB alone or in combination should be the first choice of therapy regardless of ethnic background [23]. On the other hand, patients receiving ACE inhibitor as initial treatment instead of CCB are on 51 % increase threat of having stroke [24]. Previous studies in a large trial show that compared to an ACE inhibitor, thiazide-type diuretic plays vital role in improving cerebrovascular heart failure and combined cardiovascular outcomes [25].

CONCLUSION
Assessment of CYP2C19*2 and *17 variants and HTN association has been conducted for the first time among Pakistani population. This findings indicate that the frequency of CYP2C19*2 and *17 allele are high. The findings should be helpful for physicians to determine the correct drug dosage according to individual’s metabolic capacity, lead to decreasing adverse drug reactions and improve therapeutic outcomes.

DECLARATIONS
Acknowledgement
Thanks are due to Mr. Amjad Farooq for his technical assistance, and BioMES, Alpha Genomics Private Limited, Islamabad - Pakistan for editing and reviewing the manuscript. Thanks are also due to the patients who participated in the study.

Conflict of interest
No conflict of interest is associated with this work.

Contribution of authors
We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Sana Riaz, Atika Mansoor, Saima Siddiqi, Aneesa Sultan designed all the experiments and revised the paper. Sana Riaz, Muhammad Usman Tareen, Sana Rubab, Ayesha Batool and Anwarullah performed the experiments, Sana Riaz, Atika Mansoor, Saima Siddiqi and Aneesa Sultan wrote the paper.

Open Access
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/definition), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES
1. Sukasem C, Tunthong R, Channanphon M, Santon S, Jantararongtong T, Roomdee N, Prommas S, Puangpetch A, Vathesatogkit P. CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmacogenomics Pers Med 2013; 6: 85–91.
2. Shirai N, Furuta T, Moriyama Y, Okochi K, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929–1937.
3. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008; 83: 322–327.
4. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Radstein S, Spickenheuer A, Pesch B, Brüning T, Winter S, et al. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 2009; 115: 391–396.
5. Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med 2011; 13: 987-995.
6. Zhang Y, Si D, Chen X, Lin N, Guo Y, Zhou H, Zhong D. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of glimepiride MR in Chinese subjects. Br J Clin Pharmacol 2007; 64: 67-74.
7. Chau TK, Marakami S, Kawai B, Nasu K, Kubota T, Ohnishi A. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma. Life Sci 2000; 67: 1719-24.
8. Ma Y, Ni W, Zhu W, Xiong Y, Deng X. Association of genetic polymorphisms of CYP2C19 with hypertension in a Chinese Han population. Blood Press 2011; 20: 166-170.
9. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human
subjects. JAMA 2013 Nov 27; 310(20): 2191-4. doi: 10.1001/jama.2013.281053. World Medical Association.

10. Shin DJ, Kwon J, Park AR, Bae Y, Shin ES, Park S, Jang Y. Association of CYP2C19*2 and *3 Genetic Variants with Essential Hypertension in Koreans. Yonsei Med J 2012; 53: 1115-1119.

11. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59–64.

12. Anichavezhi D, Chakradhara Roa US, Shewade DG, Krishnamoorthy R, Adithan C. Distribution of CYP2C19*17 allele and genotype in an Indian population. J Clin Pharm Ther 2012; 37: 313–8.

13. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281: 604–9.

14. Dehbozorgi M, Kamalideghghan B, Hosseini I, Dehghanian Z, Sangtarash MH, Firooz M, Ahmadpour F, Meng GY, Housmand M. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (806 C>T) alleles among an Iranian population of different ethnicities. Mol Med Rep 2018; 17: 4195–4202.

15. Zhong Z, Hou J, Li B, Zhang Q, Liu S, Li C, Liu Z, Yang M, Zhong W, Zhao P. Analysis of CYP2C19 genetic polymorphism in a large ethnic Hakka population in Southern China. Med Sci Monit 2017; 23: 6186-6192.

16. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661–66.

17. Payan M, Tajik N, Rouini MR, Ghaehremani MH. Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population. Med J Islam Repub Iran 2015; 29: 269.

18. Saeed LH, Mayet AY. Genotype-Phenotype analysis of CYP2C19 in healthy Saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci 2013; 10: 1497-502.

19. Gumus E, Karaca O, Babaoglu MO, Baysoy G, Balamtekin N, Demir H, Uslu A, Bozkurt A, Yuce A, Yasar U. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol 2012; 68: 629–36.

20. Geisler T, Schaefelfer E, Dippon J, Winter S, Buse V, Bischofs C, Zuer C, Moenike K, Gwaz M, Schwab M. CYP2C19 and non-genetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008; 9: 1251–1259.

21. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 15-21.

22. Liu PH, Wang JD. Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan. BMC Health Serv Res 2008; 8: 133.

23. Schellack N, Naicker P. Hypertension: a review of antihypertensive medication, past and present. S Afr Pharm J 2015; 82: 17-25.

24. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.

25. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.